Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.

Autor: Abiodun D Ogunniyi, Manouchehr Khazandi, Andrew J Stevens, Sarah K Sims, Stephen W Page, Sanjay Garg, Henrietta Venter, Andrew Powell, Karen White, Kiro R Petrovski, Geraldine Laven-Law, Eliane G Tótoli, Hérida R Salgado, Hongfei Pi, Geoffrey W Coombs, Dean L Shinabarger, John D Turnidge, James C Paton, Adam McCluskey, Darren J Trott

Publikováno v: PLoS ONE, Vol 12, Iss 9, p e0183457 (2017)

The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways

Externí odkaz: https://doaj.org/article/aa814e3bdf3c4940b0c7e83142c96dc3

Synthetic group A streptogramin antibiotics that overcome Vat resistance

Autor: Ian B. Seiple, Arthur A Tran, Justin T Biel, Dean L. Shinabarger, Beverly Murray, David Chow, Na Zhang, Kenneth W. Borrelli, Kaijie Ji, Gydo C. P. van Zundert, Jenna Pellegrino, D. John Lee, Cindy Wolfe, Jesslyn E Park, Ruoxi Wang, Qi Li, Olivier Chesneau, Estelle Mühle, Axel F. Brilot, Hector A Chaires, Matthew P. Jacobson, James S. Fraser

Publikováno v: Nature
Nature, 2020, 586 (7827), pp.145-150. ⟨10.1038/s41586-020-2761-3⟩
Nature, vol 586, iss 7827
Nature, Nature Publishing Group, 2020, 586 (7827), pp.145-150. ⟨10.1038/s41586-020-2761-3⟩

International audience; Natural products serve as chemical blueprints for most antibiotics in clinical use. The evolutionary process by which these molecules arise is inherently accompanied by the co-evolution of resistance mechanisms that shorten th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43735642a3593a0038eaf47b71d6765a
https://hal-pasteur.archives-ouvertes.fr/pasteur-03082400

In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile

Autor: Dean L. Shinabarger, Chris M. Pillar, Cindy Wolfe, Andrea Marra, Beverly Murray

Publikováno v: Journal of Antimicrobial Chemotherapy.

BackgroundIbezapolstat (ACX-362E) is the first DNA polymerase IIIC inhibitor undergoing clinical development for the oral treatment of Clostridioides difficile infection (CDI).MethodsIn this study, the in vitro activity of ibezapolstat was evaluated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::288b01b9b5797d5b97792d7880ec69e9
https://doi.org/10.1093/jac/dkaa134

Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis

Autor: Lynn Miesel, Clive A. Prestidge, Dean L Shinabarger, Deb Sweeney, Ramiz A. Boulos, Shasha Rao

Publikováno v: The Journal of Antibiotics

Antibiotic-resistant bacteria is a major threat to human health and is predicted to become the leading cause of death from disease by 2050. Despite the recent resurgence of research and development in the area, few antibiotics have reached the market

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08fb3ccbe8df6bd46fb14701867c5d60
https://doi.org/10.1038/ja.2016.45

Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution

Autor: Ramiz A. Boulos, Cindy Wolfe, Dean L. Shinabarger, Paul Pagano, Chris M. Pillar

Publikováno v: IndraStra Global.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license: http://creativecommons.org/licenses/by-nc-nd/4.0/ which permits use, distribution and reproduction in any medium, provided the original work is properly cited. This author a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::078a96cf5cea396966d5847076a67209
https://igi.indrastra.com/items/show/93105